ERBB2 and neoplasm: A recent study has shown that mutations in the tyrosine kinase domain of HER2 were enriched in ILC vs. IDC cases (5.7 vs. 1.4%, p < 0.0001) and associated with worse survival in ILC tumours compared to ILC HER2 wild type (66  vs. 211 months, p  =  0.0001) but not in IDC (159 vs. 166 months, p = 0.733) [47].